title: [Is folic acid effective for the prevention of cardiovascular events in patients with advanced or terminal chronic kidney disease?].
abstract: Patients with chronic kidney disease have an increased cardiovascular risk. Several non-traditional factors have been showed to be associated with this risk, including hyperhomocysteinemia. The effects of reducing homocysteine levels with folic acid supplementation have been studied in a number of randomized trials, with mixed results. In this article we critically appraise two systematic reviews providing disparate conclusions about this question and we summarize their main findings using the GRADE methodology. We conclude that there are methodological differences that may explain the mixed results in both systematic reviews. Folic acid supplementation does not reduce cardiovascular morbidity or mortality in patients with chronic kidney disease at any stage.
authors.forename: José
authors.initials: J
authors.lastname: Peña
authors.forename: Juan Carlos
authors.initials: JC
authors.lastname: Claro
mesh_terms: D002318:Cardiovascular Diseases / Q000209:etiology / Q000517:prevention & control*; D005492:Folic Acid / Q000627:therapeutic use*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications*; D016032:Randomized Controlled Trials as Topic
chemical_list: D005492:Folic Acid